United States · Health startup
United States · Veramarx, Inc.
Veramarx offers the only accurate diagnostic test for early-stage Lyme disease, which is one of the fastest growing infectious disease in the US and Western Europe.
Funding reportedLast round: Seed
About Veramarx, Inc.
Veramarx offers the only accurate diagnostic test for early-stage Lyme disease, which is one of the fastest growing infectious disease in the US and Western Europe.
Lyme disease can only be treated effectively when diagnosed at the early stage of infection, when 75% of patients visit the doctor. Current tests are highly inaccurate, missing over 60% of the cases in the early stage.
What company datasets say Veramarx, Inc. raised
Funding, as reported
The company, in detail
What they build
Known for
lyme disease early presentationhealth carelyme disease clinical testmolecular diagnosticslyme disease antibody alternativesbiomarker immunoassayhigh sensitivity lyme testlyme disease testearly stage lyme detectionlyme disease clinical validationlyme disease negative predictive valuelyme disease diagnostic innovationlyme disease biomarkers measurementearly treatment lymelyme diseasehospital & health care
Built with from their website
Google Cloud Hosting
- Sector
- Health
- Industry code
- NAICS 62151, SIC 8731
- Region
- Colorado
- Full record
- Every detail in the company directory
Health in United States
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Veramarx, Inc. in front of investors. Or tell us what we have wrong.